Legend Biotech (LEGN) Liabilities and Shareholders Equity (2019 - 2025)
Legend Biotech filings provide 7 years of Liabilities and Shareholders Equity readings, the most recent being $1.7 billion for Q4 2025.
- On a quarterly basis, Liabilities and Shareholders Equity rose 3.8% to $1.7 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $6.8 billion, a 3.25% decrease, with the full-year FY2025 number at $1.7 billion, up 3.8% from a year prior.
- Liabilities and Shareholders Equity hit $1.7 billion in Q4 2025 for Legend Biotech, up from $1.7 billion in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $615.3 billion in Q1 2021 to a low of $813.8 million in Q3 2021.
- Median Liabilities and Shareholders Equity over the past 5 years was $1.7 billion (2025), compared with a mean of $35.6 billion.
- The widest YoY moves for Liabilities and Shareholders Equity: up 55.03% in 2021, down 99.89% in 2021.
- Legend Biotech's Liabilities and Shareholders Equity stood at $1.1 billion in 2021, then grew by 18.89% to $1.3 billion in 2022, then skyrocketed by 38.89% to $1.8 billion in 2023, then fell by 9.65% to $1.7 billion in 2024, then rose by 3.8% to $1.7 billion in 2025.
- The last three reported values for Liabilities and Shareholders Equity were $1.7 billion (Q4 2025), $1.7 billion (Q3 2025), and $1.7 billion (Q2 2025) per Business Quant data.